Eli Lilly and Co (LLY.US) expects that the new weight loss drug will be approved early next year.

AASTOCKS · Jan 14 02:43

Eli Lilly and Co CEO Dave Ricks stated that its experimental weight-loss drug orforglipron is expected to be approved as early as early 2026.

Ricks mentioned that the pills would be more convenient for patients and easier to produce on a large scale. The shortage of injections for weight loss under Eli Lilly and Co is partly due to production limitations.

The translation is provided by third-party software.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.

禮來公司(LLY.US)料新減肥藥將於明年初獲批准

Eli Lilly and Co (LLY.US) expects that the new weight loss drug will be approved early next year.

Risk Disclaimer

Statement